Company Overview

Daré Bioscience, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing products in women’s health. The company operates primarily within the biotechnology and specialty pharmaceutical industries, with a strategic emphasis on reproductive health, contraception, sexual health, fertility, and menopause-related conditions. Daré’s business model centers on advancing a portfolio of clinical-stage and commercial-stage therapeutic candidates through internal development, licensing arrangements, strategic collaborations, and commercialization partnerships.

The company’s primary revenue drivers have historically included licensing agreements, collaboration payments, grant funding, and, to a lesser extent, product-related revenue associated with partnered commercialization efforts. Daré has positioned itself as a women’s health-focused innovator targeting areas that have historically seen limited pharmaceutical investment, particularly non-hormonal and patient-centric treatment options. The company traces its origins to a reverse merger completed in 2017 between Cerulean Pharma Inc. and Daré Bioscience Operations, Inc., after which the combined entity adopted the Daré Bioscience name and strategy focused exclusively on women’s health therapeutics.

Business Operations

Daré Bioscience organizes its operations around the development and advancement of a diversified women’s health portfolio rather than through large independent operating divisions. Key development programs have included XACIATO (bacterial vaginosis treatment), Sildenafil Cream, 3.6% for female sexual arousal disorder, Ovaprene contraceptive technology, and intravaginal and hormone-related therapeutic candidates targeting reproductive and sexual health conditions. The company generates revenue primarily through licensing transactions, milestone payments, collaborative development agreements, and commercialization partnerships. Daré has relied heavily on intellectual property licensing and external development partnerships to advance its pipeline while maintaining a relatively asset-light operational structure.

The company’s operations are primarily U.S.-based, though several licensing and commercialization relationships have international implications. Daré controls or licenses a portfolio of patents, formulations, and drug-delivery technologies associated with women’s reproductive and sexual health. Important strategic relationships have included agreements with Organon, Bayer, and other pharmaceutical or development partners connected to commercialization and clinical advancement efforts. Public filings also indicate collaboration with academic institutions, contract research organizations, and manufacturing partners to support clinical development and regulatory activities.

Strategic Position & Investments

Daré Bioscience’s strategic direction has focused on building a diversified women’s health portfolio spanning contraceptive products, vaginal health therapies, sexual health treatments, and fertility-related technologies. The company has pursued a strategy of acquiring or licensing underdeveloped clinical assets and advancing them through regulatory pathways using targeted capital deployment and strategic partnerships. A major milestone in this strategy was the U.S. FDA approval of XACIATO, a clindamycin phosphate vaginal gel developed for bacterial vaginosis and commercialized through partnership arrangements.

The company has continued investing in late-stage and differentiated candidates, including non-hormonal contraceptive technologies and therapeutics addressing female sexual dysfunction. Daré’s portfolio approach is intended to diversify clinical and commercial risk across multiple women’s health categories rather than rely on a single flagship product. Public disclosures in SEC filings and investor materials indicate ongoing emphasis on strategic licensing, capital-efficient development models, and potential out-licensing opportunities for regional or global commercialization rights. Some pipeline programs remain in clinical development stages, and timelines or commercial prospects for certain candidates remain subject to regulatory review and financing conditions.

Geographic Footprint

Daré Bioscience is headquartered in San Diego, California, and its core operational activities are concentrated in the United States. The company’s primary regulatory and commercial focus has historically been the U.S. healthcare market, particularly through interactions with the U.S. Food and Drug Administration and domestic commercialization partners.

Despite its relatively small operational footprint compared with large pharmaceutical companies, Daré maintains international relevance through licensing rights, intellectual property agreements, and development collaborations that may extend into Europe, Canada, and other global pharmaceutical markets. The company’s products and pipeline candidates are positioned for potential international commercialization through strategic partnerships rather than direct multinational infrastructure ownership. Publicly available information indicates that Daré’s global influence is primarily driven by intellectual property and licensing arrangements rather than extensive overseas operations.

Leadership & Governance

Daré Bioscience’s leadership team is composed of biotechnology, pharmaceutical, and women’s health executives with experience in clinical development, regulatory affairs, commercialization, and corporate finance. The company’s governance strategy has emphasized advancing differentiated women’s health therapies while leveraging partnerships to manage development costs and commercialization risk. Corporate messaging from management has consistently focused on addressing unmet needs in women’s health through innovation, strategic licensing, and disciplined capital allocation.

Key executives include:

• Sabrina Martucci Johnson – President and Chief Executive Officer
• Richard L. Franco, Jr. – Chief Financial Officer
• David A. Friend, Ph.D. – Chief Medical Officer
• John A. Fair – Chief Strategy Officer

Information regarding leadership roles and corporate governance has been consistently disclosed through SEC filings, company investor presentations, and public corporate communications. Certain operational details related to future strategic initiatives or unannounced partnership discussions remain limited to publicly available disclosures.